Comparative Pharmacology
Head-to-head clinical analysis: ETRAFON 2 10 versus PERSERIS KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAFON 2 10 versus PERSERIS KIT.
ETRAFON 2-10 vs PERSERIS KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ETRAFON 2-10 is a combination of the phenothiazine antipsychotic perphenazine and the tricyclic antidepressant amitriptyline. Perphenazine blocks dopamine D2 receptors, reducing dopaminergic neurotransmission in the mesolimbic pathway, while amitriptyline inhibits serotonin and norepinephrine reuptake, enhancing monoaminergic signaling.
Risperidone, the active component of PERSERIS, is an atypical antipsychotic with antagonist activity at dopamine D2 and serotonin 5-HT2A receptors. It also binds to α1-adrenergic, α2-adrenergic, and histamine H1 receptors.
1-2 tablets (perphenazine 2 mg / amitriptyline 10 mg) orally 3-4 times daily; max 8 tablets/day.
Subcutaneous injection: 90 mg every 28 days for maintenance treatment of schizophrenia.
None Documented
None Documented
The terminal elimination half-life is approximately 9-10 hours for perphenazine and 18-24 hours for amitriptyline; amitriptyline's active metabolite nortriptyline has a half-life of 18-44 hours, necessitating once-daily dosing for maintenance.
Terminal elimination half-life is approximately 15 days (range 10-20 days) for the extended-release injectable formulation, reflecting slow release from the depot and sustained plasma concentrations.
Elimination is primarily renal (50-70% as metabolites, <5% unchanged) and biliary/fecal (30-50% as metabolites).
Primarily hepatic metabolism via CYP2D6 and CYP3A4; approximately 30-40% of a dose is excreted in urine as metabolites, with less than 1% as unchanged drug. Biliary/fecal elimination accounts for about 60-70%.
Category C
Category C
Antipsychotic/Antidepressant Combination
Antipsychotic